Ashley Gallagher, Associate Editor

The medication has both short- and long-term effects on improving excessive sleepiness.

Anna Legreid-Dopp, PharmD, Senior Director of Clinical Guidelines and Quality Improvement at the American Society of Health-System Pharmacists discusses Pfizer’s request to approve their COVID-19 vaccine for children 5 to 11.

Avacopan (Tavneos, ChemoCentryx) met its primary endpoints of disease remission at 26 weeks and sustained remission at 52 weeks during a phase 3 trial in patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis.

Investigators from the University of Houston find that 45% of the positive samples were from the soles of shoes.

CAR-NK therapies are also shown to have fewer adverse reactions, and 25% of mice that were treated remained disease-free.

Those who are younger than aged 40 years tend to regain these senses at higher rates than those who are older.

A town hall meeting with representatives from the agencies emphasized the effectiveness and likelihood of getting a third dose of the vaccine.

New legislation in New York state seeks to address flaws in prescription drug distribution system.

In a study, individuals who were taking prucalopride had better memory tests and fMRI scans indicating enhanced brain activity in relation to cognition.

AZD7442 (AstraZeneca), a long-acting antibody combination, reduced the risk of developing symptomatic COVID-19 by 77% compared to placebo.

Labcorp’s collection kit can simultaneously detect the coronavirus and influenza A/B in individuals aged 2 years and older, and results can be determined in 1 to 2 days.

Study results show KNT-127 is a promising therapeutic option and enhances the anti-inflammatory response.

With the Delta variant, there was an increase in coronavirus-related hospitalizations by more than one-third among these individuals.

Axsome Therapeutics continues to explore its narcolepsy drug after the FDA granted it orphan drug designation.

In a Pharmacy Times® interview, Jessica Hui, a researcher and pediatric allergist at National Jewish Health, discussed how increased hand hygiene may be harming the hands of healthcare workers.

The main factors behind the vaccine hesitancy are the potential adverse effects post-vaccination and effect on their autoimmune conditions, as well as lack of trial data, an analysis shows.

The medication receives the approval after it was shown to be more effective than daily tenofovir disoproxil fumarate with emtricitabine tablets.

The agency has given the greenlight to maralixibat after the ICONIC study combined with 5 years of supportive studies that demonstrated the reduction of pruritis.

Individuals who used intranasal corticosteroids prior to being infected were about 22% less likely to be hospitalized from severe COVID-19 than those who did not.

Rivaroxaban (Xarelto, Janssen) demonstrates a lower incidence of bleeding events in pediatric patients.

T2D is associated with a higher mortality risk linked to the coronavirus than individuals with T1D.

Study shows that shedding pounds potentially decreases the risk of diabetes, dyslipidemia, and high blood pressure.

The medication has met the criteria of overall survival for individuals with this type of liver cancer who were previously treated with sorafenib, Merck says.

Patients with senile dementia who have silent epileptic activity show improvement when taking this medication.

Study results presented at an American Heart Association conference show that 34% of individuals have high blood pressure.

Investigators at Stanford Medicine find that 72% of individuals who took the highest dose of ON-SXB were considered much or very much improved.

Treatment of round pneumonia should be followed up with a 2-view chest X-ray weeks later.

An intravenous immunoglobulin option along with glucocorticoids could be effective in fighting drug-induced erythroderma for patients with AIDS.

Study shows Lefamulin, omadacycline, ceftaroline, delafloxacin are beneficial in treating community-acquired pneumonia.

The overall response rate of ruxolitinib at week 24 was 49.7% compared with 25.6% for the best available therapy treatment for graft-versus-host-disease.